Who makes [177Lu]Lu-DOTA-TATE?

[177Lu]Lu-DOTA-TATE is developed by Novartis Pharmaceuticals.

What development phase is [177Lu]Lu-DOTA-TATE in?

[177Lu]Lu-DOTA-TATE is in Phase 1.

Last reviewed 2026-05-15 · How we verify

[177Lu]Lu-DOTA-TATE

Novartis Pharmaceuticals · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	[177Lu]Lu-DOTA-TATE
Also known as	Lutathera, Lutetium (177Lu)oxodotreotide, Lutetium Lu 177dotatate, Lutetium (177Lu) oxodotreotide, Lutetium Lu 177 dotatate
Sponsor	Novartis Pharmaceuticals
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[177Lu]Lu-DOTA-TATE CI brief — competitive landscape report
[177Lu]Lu-DOTA-TATE updates RSS · CI watch RSS
Novartis Pharmaceuticals portfolio CI